SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Rep

Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycard

LXEO

Related stories